의약품, 바이오테크놀러지, 진단약의 인수합병(M&A) 거래(2020-2024년)

Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology and diagnostics sectors. Fully revised and updated, the report provides details of 2,269 M&A agreements from January 2020 to June 2024.

The report provides a detailed understanding and analysis of how and why companies enter M&A deals. The majority of deals are acquisitions whereby the acquirer acquires the target company in a cash and/or equity transaction.

Merger and acquisition is a constant activity within the biopharma sector. In the past, biopharma companies have sought to merge or acquire competitor companies in order to achieve critical mass both in R&D and sales and marketing, thus ensuring continued growth and dominance in a highly competitive and global marketplace.

In 1987, the largest ten companies were responsible for approximately twelve percent of global pharmaceutical sales. By 2002, this figure had become nearly fifty percent. This concentration was principally due to big pharma mega mergers.

The rewards offered for the successful marketing and sale of a blockbuster drug are enormous, therefore it is not surprising to see big pharma seeking ways of maximizing returns. Licensing has often been a means of achieving such global presence, but increasingly big pharma has sought to acquire its way into the major pharmaceutical markets. Until recently the mega merger was a popular means of growing presence globally; however the last few years have seen a concentration on smaller acquisitions to bolster R&D pipelines.

This report focuses on M&A between big pharma-big pharma, big pharma - smaller company, big biotech-big biotech, big biotech - smaller company, and smaller company-smaller company, providing a detailed insight into all such deals.

This report contains links to M&A deal records since 2020, including where available online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

The initial chapters of this report provide an orientation of M&A dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in M&A as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of M&A deals. The chapter includes numerous case studies to enable understanding of M&A deals.

Chapter 4 provides a review of the leading M&A deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 50 most active biopharma companies in M&A. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a comprehensive review of M&A financials for deals announced since 2020, including headline value, providing both benchmark data and access to individual deal financials.

Chapter 7 provides a comprehensive and detailed review of M&A deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in M&A deal making since 2020.

In addition, a comprehensive deal directory is provided organized by M&A company A-Z, and therapeutic target. Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about M&A partnering in the research, development and commercialization of technologies and products.

Key benefits

M&A Deals in Pharmaceuticals, Biotechnology and Diagnostics provides the reader with the following key benefits:

• Understand M&A deal trends since 2020
• Browse 2,232 M&A deals
• Benchmark analysis - identify market value of transactions
• Understand agreed financial terms
• Directory of deals by company A-Z, therapy focus
• Leading M&A deals by value
• Most active M&A dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into M&A deal structures
• Due diligence - assess suitability of your proposed deal terms
• Save hundreds of hours of research time
• M&A Deals in Pharmaceuticals, Biotechnology and Diagnostics is intended to provide the reader with an in-depth understanding of M&A trends and structure of deals entered into by leading biopharma companies worldwide.

M&A Deals in Pharmaceuticals, Biotechnology and Diagnostics includes:

• Trends in M&A dealmaking in the biopharma industry
• Overview of M&A deal structures
• Directory of M&A deal records covering pharmaceutical, biotechnology and diagnostics
• The leading M&A deals by value
• Most active M&A dealmakers

In M&A Deals in Pharmaceuticals and Biotechnology, available deals are listed by:

• Company A-Z
• Industry sector
• Therapeutic area
• Each deal title links via weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company agreements allows assessment of the following:

• What are the precise merger or acquisition terms agreed between the parties?
• What is the plan of merger and how will it be implemented?
• What is actually being acquired by the acquiring company?
• What is the payment structure for the deal?
• What are conditions of merger or acquisition?
• What are the rights of shareholders and dissenters?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for what in the acquisition?
• How is confidentiality and publicity managed?
• Under what conditions can the deal be terminated?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from acquisition to acquisition?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in M&A dealmaking

• 2.1. Introduction
• 2.2. Difference between merger and acquisition deals
• 2.3. Trends in M&A deals since 2020
  • 2.3.1. M&A dealmaking by year since 2020
  • 2.3.2. M&A dealmaking by industry sector since 2020
  • 2.3.3. M&A dealmaking by therapy area since 2020
  • 2.3.4. M&A dealmaking by most active company since 2020
• 2.4. Key M&A trends
• 2.5. Option to acquire the new acquisition?
• 2.6. When M&A can be useful
• 2.7. Attributes of M&A deals
  • 2.7.1. M&A as an alternative to IPO
• 2.8. Partnering deals with M&A component
  • 2.8.1. Partnering as a precursor to M&A
  • 2.8.2. Equity as part of partnering deal
  • 2.8.3. Conversion of partnership to acquisition
  • 2.8.4. But M&A is not always the route followed
• 2.9. Big pharma mega mergers - are we at the end of the road?
  • 2.9.1. Growth of Johnson & Johnson through M&A
  • 2.9.2. Growth of Novartis through M&A
• 2.10. Accessing innovation through M&A
  • 2.10.1. Big pharma acquisitions of small companies
  • 2.10.2. Medium and small biopharma - use of M&A
  • 2.10.3. Using M&A to build a company
  • 2.10.4. Emergence of biotech-biotech mergers
• 2.11. The emerging role of private equity in M&A
• 2.12. Implementing M&A transactions
• 2.13. Joint ventures as alternative to M&A
• 2.14. The future of M&A in biopharma

Chapter 3 - Overview of M&A deal structure

• 3.1. Introduction
• 3.2. Pure versus multi-component acquisition deals
• 3.3. Pure M&A agreement structure
• 3.4. Acquisition as part of a wider alliance agreement
• 3.5. Merger agreements

Chapter 4 - Leading M&A deals

• 4.1. Introduction
• 4.2. Top M&A deals by value

Chapter 5 - Top 25 most active M&A dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active M&A dealmakers

Chapter 6 - M&A contract directory since 2020

• 6.1. Introduction
• 6.2. M&A deals with contracts since 2020
• Deal Directory
• Deal Directory - M&A deals by company A-Z
• Deal Directory - M&A deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of merger and acquisition
• Figure 2: Trends in M&A deal announcements, 2020-2024
• Figure 3: M&A deals by industry sector, 2020-2024
• Figure 4: M&A deals by therapy area, 2020-2024
• Figure 5: Top 50 most active M&A dealmakers, 2020-2024
• Figure 6: Key recent M&A trends - 2020-2024
• Figure 7: Situations where M&A can prove useful
• Figure 8: Recent partnering deals involving equity participation in the licensor
• Figure 9: Equity investments converting to acquisitions
• Figure 10: Issues in implementing M&A agreements
• Figure 11: Future trends in M&A in biopharma
• Figure 12: Components of the acquisition deal structure
• Figure 13: Components of the merger deal structure
• Figure 14: Top M&A deals by value 2020-2024
• Figure 15: Most active M&A dealmakers 2020-2024